

BD Acquires Venclose to enhance treatment for Chronic Venous Disease

03 December 2021 | News

Adding transformative solutions to its existing venous disease portfolio with the potential to reshape patient care

BD (Becton, Dickinson and Company) has acquired Venclose, Inc., a provider of solutions for the treatment of chronic venous insufficiency (CVI), a disease that is the result of malfunctioning valves and can lead to varicose veins.

Venclose is a leader in CVI treatment through its innovative Radio Frequency (RF) ablation technology platform designed for versatility, efficiency and simplicity. RF ablation is the predominant treatment of CVI and has wide acceptance among physicians. Compared to the alternative laser treatment therapy for CVI, RF ablation catheters can potentially reduce post-operative pain and bruising in patients.

The Venclose™ System is compactly designed and provides two heating length sizes (2.5 cm and 10 cm) in one 6 FR sized catheter. This dynamic dual heating length catheter provides multiple operational benefits to physicians.

With 30 percent more heating length than the longest leading competitive RF ablation catheter, the Venclose™ System can enable physicians to efficiently ablate more vein during each heating cycle and help to lower the total number of ablations required for in-vein treatment.